Generic Name and Formulations:
Beractant (as phospholipids) 25mg/mL; susp for intratracheal administration; preservative-free.
Indications for SURVANTA:
Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.
See literature for dosing chart, administration, and additional support procedures. 100mg of phospholipids (4mL)/kg birth weight per dose, by intratracheal administration; max 4 doses, at 6-hr intervals in the first 48hrs after birth. Rescue: give 1st dose as soon as possible after infant is placed on mechanical ventilation for treatment of RDS. Prevention: give 1st dose as soon as possible after birth, preferably within 15 mins. Avoid suctioning for 1 hour after treatment, unless significant airway obstruction occurs. Retreatment is determined by continued respiratory distress. Get radiographic confirmation of RDS in those infants given preventative dose before giving additional doses.
Interrupt dosing if bradycardia or oxygen desaturation occurs; treat; resume after stabilization. Monitor oxygenation, carbon dioxide, and clinical condition frequently and carefully.
Dosing procedure reactions including oxygen desaturation and bradycardia, rales, moist breath sounds, sepsis, intracranial hemorrhage.
Vials (4mL, 8mL)—1
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder